Company: INTS
Filing Date: 2025-04-24
Form Type: S-1/A
Source: 0001628280-25-019491
Chunk: 29

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-24
Form: S-1/A
Chunk 29
---
 2025), and after deducting estimated Placement Agents’ fees and estimated offering expenses payable by us, and assuming no sale of any Pre-Funded Warrants in this offering and no exercise of the Common Warrants issued in connection with this offering, our pro forma as adjusted net tangible book value as of December 31, 2024 would have been $5.3 million, or $0.30 per share of Common Stock. This represents an immediate increase in pro forma as adjusted net tangible book value of $0.12 per share to our existing shareholders and an immediate dilution of $1.00 per share to investors participating in this offering based on the assumed public offering price. We determine dilution per share to investors participating in this offering by subtracting pro forma as adjusted net tangible book value per share after this offering from the assumed public offering price per share paid by investors participating in this offering. The information above is illustrative only and will change based on actual pricing and other terms of this offering determined at pricing. The final public offering price will be determined through negotiation between us and the Placement Agents in the offering and may be at a discount to the current market price. Therefore, the assumed offering price used throughout this prospectus may not be indicative of the final public offering price.

The following table illustrates this dilution on a per share basis:

| Assumed public offering price per share                                                      |     |   |      |     | $ | 1.30 |
| Net tangible book value per share as of December 31, 2024                                    |     | $ | 0.18 |     |   |      |
| Increase in net tangible book value per share attributable to new investors in this offering |     | $ | 0.12 |     |   |      |
| As adjusted net tangible book value per share after this offering                            |     |   |      |     | $ | 0.30 |
| Dilution in net tangible book value per share to new investors in this offering              |     |   |      |     | $ | 1.00 |

Each $1.00 increase or decrease in the assumed public offering price of $1.30 per share of Common Stock and accompanying Common Warrants, the last reported sale price of our Common Stock on the Nasdaq Capital Market on April 23, 2025, would increase or decrease our pro forma as-adjusted net tangible book value per share after this offering by $0.12 per share. Each $1.00 increase